We reported that AS101 (organotellurium compound, trichloro(dioxoethylene-O,O′) tellurate) inhibited the differentiation of Th17 cells and reduced the production of IL-17 and GM-CSF. In addition, AS101 promoted the production of IL-2 in activated T cells. Flow cytometric analysis showed that AS101 inhibited Th17 cell proliferation. AS101 blocked the activation of transcriptional factor NFAT, Stat3, and RORγt, and increased activation of Erk1/2, suggesting a mechanism of action of AS101. We further demonstrated that AS101 was effective in amelioration of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis. Finally, by real-time PCR analysis we showed that AS101 reduces the IL-17, IFN-γ, GM-CSF, and IL-6 mRNA expression in inflammatory cells of spinal cords. Additionally, flow cytometry analysis also indicated that the CD4+ T cells and IL-17 and GM-CSF-producing cells were reduced in the spinal cords of AS101 treated mice compared to those treated with PBS.
Introduction
Multiple sclerosis (MS) is a debilitating autoimmune disease characterized by both inflammation and axonal degeneration. The resulting demyelination and subsequent degeneration of axons account for the disability of patients with MS (Calabresi, 2002) . MS is estimated to affect 400,000 persons in the United States and 2 million people worldwide (Calabresi, 2002) . Drugs that are commonly used for MS include corticosteroids, interferons, glatiramer (Copaxone), natalizumab (Tysabi), mitoxantrone (Novantrone), fingolimod (Gilenya), and teriflunomide (Aubagio). The limited effectiveness of these approved treatments for MS, as well as reports of adverse events and toxicity, such as severe liver damage, shortness of breath after injection, brain infection and cardiopathology following a mitoxantrone treatment, emphasize the need for the development of new therapies with improved efficacy and reduced side-effects (Calabresi, 2002; Friese et al., 2006; Ulzheimer et al., 2010) . Hence, there is a need for additional treatment options in MS.
Experimental autoimmune encephalomyelitis (EAE) is an animal model of human MS. Increased understanding of the underlying pathophysiology of the disease and advances in developing new biotechnology has led to new therapeutic approaches to the treatment of MS. Early studies indicated that CD4 + T cells are effectors for disease progression (Hohlfeld and Wekerle, 2001 ) and EAE can be induced by adoptive transfer of myelin-specific CD4 + Th1 cells into naïve recipients (Waldburger et al., 1996) . However, cytokine IFN-γ is not required for development of EAE since IFN-γ −/− or IFN-γR −/− mice develop more severe EAE than wild type counterparts (Ferber et al., 1996) . It is postulated that the differentiation pathway that generate Th1 cells may be important in encephalitogenicity, but the downstream production of IFN-γ by myelin-specific T cells is not critical (Lovett-Racke et al., 2011) . Further animal model study showed that IFN-γ and central nervous system (CNS) able to respond to IFN-γ are important for inflammation of the spinal cord (Lees et al., 2008) , which is consistent with the clinical trial that treatment of MS with IFN-γ exacerbates the severity of MS (Panitch et al., 1987) . In addition, recent studies identified additional contributions to disease pathogenesis, including IL-17-producing T cells, B cells, and
